Navigation Links
Genetix Joins Molecular Devices: Combining Businesses to be in a Better Position to Serve Customers
Date:7/5/2011

SUNNYVALE, Calif., July 5, 2011 /PRNewswire/ -- Today, Molecular Devices, a leading provider of instruments, software, and consumables for drug discovery and life sciences research, announced that the Drug Discovery Division of Genetix will join Molecular Devices.

(Logo:  http://photos.prnewswire.com/prnh/20100406/SF82092LOGO)

With the addition of Genetix, Molecular Devices continues to grow as a leading technology supply company for research, biotechnology, and pharmaceutical customers around the world.

Research in Pharma/Biotech is shifting toward biotherapeutic drugs (antibodies, proteins, and vaccines).  Two key products from Genetix, the ClonePix™ and QPix™ instrument platforms, address cell lines used in biotherapeutic research.  ClonePix is an automated mammalian cell selection platform that significantly expedites the process of identifying and selecting cells that produce biotherapeutic candidates, reducing both time and cost.

In addition, the CloneSelect™ Imager and CellReporter from Genetix will extend Molecular Devices' imaging portfolio. These products offer a good value for a budget conscious end user.

Commenting on the move, Mark Verheyden, President of Molecular Devices said, "We are excited about welcoming Genetix into the Molecular Devices team, knowing that the combined business will be better positioned to serve our customers."

About Molecular Devices, Inc.

At Molecular Devices we have one focus—our customers. Whether a long-time user, recent adopter, or prospective customer, your needs fuel our actions. We hire creative, best-in-class people to design, manufacture, and commercialize analytical instruments, software, and assays as well as provide dedicated follow-on support. Understanding your laboratory workflow is our top priority, and we direct product development toward solving your unique issues. Our instruments offer a full spectrum of detection technologies and meet all throughput needs—from dedicated, single-readout devices to multi-readout systems. Our goal is to deliver highly relevant analytical products to detect biology, decode data, and drive discovery. With headquarters in Silicon Valley and offices around the globe, we support and enrich efforts of the international BioResearch, BioPharma, and BioTesting communities. Visit us today at www.MolecularDevices.com.

Molecular Devices products are for Research Use Only. Not for use in diagnostic procedures.

Molecular Devices, the Molecular Devices logo, and all other trademarks are the property of Molecular Devices, Inc.

About Genetix

Founded in 1991, Genetix offers cell selection and cell imaging instrumentation and related products to basic and applied research scientists. The product range has been rebranded to carry the Molecular Devices name.


'/>"/>
SOURCE Molecular Devices Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Imagenetix, Inc. Reports Third Quarter 2011 Results
2. Imagenetix, Inc. Provides Net Sales Guidance for the Second Quarter Fiscal 2011
3. Imagenetix Announces Issuance of New U.S. Patent for the Prevention and Treatment of Periodontal Disease
4. Letter to Shareholders From Imagenetix, Inc. President/CEO William Spencer
5. Bacterin Joins Russell 3000, Russell Microcap, and Russell Global Indexes
6. Drs. Ben Machielse Joins Omthera Pharmaceuticals, Inc. as Chief Operating Officer
7. Alan Dunton, M.D., Joins Board of Directors of Palatin Technologies, Inc.
8. Radient Pharmaceuticals Corporation Joins OTCQX
9. Dr. Assad Al-Ammar Joins Irvine Pharmaceutical Services as the New Minerals Analysis Manager in Response to the Growing Needs for USP Elemental Impurities Testing
10. Dr. F. John Mills Joins Intelsius Board of Directors as Non-Executive Chair
11. Mr. Charlie Alvarez Joins the Board of Sanomedics International Holdings, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Calif. , June 23, 2016 Any dentist ... many challenges of the current process. Many of them do ... of the technical difficulties and high laboratory costs involved. And ... to offer it at such a high cost that the ... it. Dr. Parsa Zadeh , founder of ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... Ill. and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment ... Astellas Farma Brasil as the company,s second affiliate in Latin America . ... ... General Manager of Astellas Farma Colombia ... ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users ... - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 ... Pro X . Simply select a ProHand generator and drag it above media or ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
(Date:6/24/2016)... Plano, TX (PRWEB) , ... June 24, 2016 , ... ... taking part in Genome magazine’s Code Talker Award, an essay contest in which patients ... for an award to be presented at the 2016 National Society of Genetic Counselors ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm ... sciences executive with extensive sequencing and genomics experience, as Vice President of North American ... Hill will be responsible for leading the sales team in the commercialization of the ...
Breaking Medicine News(10 mins):